BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,196,044 | +11.8% | 121,200 | -27.1% | 3.66% | -3.0% |
| Q2 2023 | $2,858,640 | -43.4% | 166,200 | -45.5% | 3.78% | -33.9% |
| Q1 2023 | $5,051,926 | +58.2% | 304,700 | -27.3% | 5.71% | +87.7% |
| Q4 2022 | $3,192,780 | -37.4% | 419,000 | -18.4% | 3.04% | -42.9% |
| Q3 2022 | $5,102,000 | +20.5% | 513,300 | +10.1% | 5.33% | +12.2% |
| Q2 2022 | $4,233,000 | -10.5% | 466,200 | 0.0% | 4.74% | +9.1% |
| Q1 2022 | $4,732,000 | -39.1% | 466,200 | 0.0% | 4.35% | -28.3% |
| Q4 2021 | $7,776,000 | – | 466,200 | – | 6.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |